Novel anti-cancer therapy: Prevention or reversal of cancer resistance

CatalYm Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab

18-Jul-2024 - CatalYm announced the completion of a $150 million Series D financing. The oversubscribed round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion’s Growth Opportunities Fund (“Forbion Growth”), Omega Funds and Gilde Healthcare. Existing investors Jeito Capital, ...

SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases

Novel and potentially groundbreaking therapeutic strategy

10-Jul-2024 - SciRhom GmbH announced the closing of a EUR 63 million (USD 70 million) Series A financing round. The round was co-led by Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Partners, with participation from new investor Bayern Kapital and existing investors including ...

Almost two million euros for biotech start-up

BMBF funds DKFZ spin-off for the development of an antibody therapy against pancreatic cancer

12-Jun-2024 - Panosome GmbH, a biotech company founded in Heidelberg in 2020, specializes in the development of monoclonal antibodies for a wide range of medical purposes. The basis for this is the VAST technology platform jointly developed by Panosome and DKFZ. Panosome now wants to use the VAST technology to ...

Calluna Pharma launches and announces EUR 75 million Series A financing to develop novel therapies for inflammatory and fibrotic diseases

Calluna Pharma has a pipeline of selective antibodies targeting immunological diseases

01-Feb-2024 - Oxitope Pharma (Oxitope) and Arxx Therapeutics (Arxx), companies with a shared goal of leveraging the innate immune system to discover and develop disease modulating therapies, announced their merger to form Calluna Pharma Inc. (Calluna). Calluna has raised EUR 75 million in a series A financing ...

Calypso Enters into Agreement to Be Acquired by Novartis

09-Jan-2024 - Calypso Biotech BV, a leader in the development of Interleukin15 (IL-15) targeted therapies, announced that it has entered into an agreement to be acquired by Novartis AG. Calypso’s shareholders will receive an upfront payment of $250 million upon closing and are eligible to receive development ...

A promising investigational therapeutic monoclonal antibody to treat chronic hepatitis B and D infections

08-Aug-2023 - Affecting hundreds of millions of people, chronic hepatitis B is a widespread global health problem for which there is as yet no cure. In a preclinical study involving the German Center for Infection Research (DZIF), Heidelberg University Hospital, University Medical Center Hamburg-Eppendorf and ...

Waters and Sartorius Expand Collaboration to Deliver Comprehensive Bioanalytics for Downstream Biomanufacturing

06-Jun-2023 - Waters Corporation and Sartorius announced a new collaboration to develop integrated analytical solutions for downstream biomanufacturing, expanding their joint agreement that began with upstream bioprocessing analytics. Software and hardware integrations between the Waters™ PATROL™ ...

CatalYm Closes EUR 50 Million Series C Financing

Start-up develops a "new anti-cancer immunotherapeutic drug with the potential to transform the immuno-oncology landscape"

24-Nov-2022 - CatalYm announced the close of a EUR50 million (USD49 million) Series C financing round. The oversubscribed round was co-led by new investors, Brandon Capital and Jeito Capital with participation from existing investors Forbion, Novartis Venture Fund, Vesalius Biocapital III, Bayern Kapital, ...

New proteins that mimic immunoglobulins in antibodies could lead to more effective drug design

CSIC researchers participate in a study that uses computational design to obtain proteins with better properties and a more precise mechanism of action

07-Oct-2022 - Researchers from the Spanish National Research Council (CSIC) and the Institute for Protein Design have co-designed and created new proteins, non-existent in nature, with structures that mimic the immunoglobulins of antibodies, which are the proteins used by the immune system to identify and ...

Merck Boosts Commercial Capacity in France

Merck has opened a commercial facility for its new Millipore® CTDMO Services offering at the company’s site in Martillac, France

04-Oct-2022 - Merck has opened a commercial facility for its new Millipore® CTDMO Services offering at the company’s site in Martillac, France. The 2,700-square-meter facility will provide global supply of commercial drug substances, including monoclonal antibodies (mAbs) and other recombinant proteins, from ...